The Oncology Institute

The Oncology Institute, Inc. provides cancer care treatment services. It offers evidence-based cancer care to patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. The company is headquartered in Cerritos, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The Oncology Institute reports strong revenue growth amidst operational challenges

TOI's Q1 2024 performance showcased robust revenue growth driven by strategic partnerships and record prescription sales, despite challenges with drug margin compression.
Operational achievements and a healthy cash position provide a strong foundation for TOI to navigate challenges and capitalize on growth opportunities in the oncology market.
By focusing on strategic priorities outlined by CEO Daniel Virnich, TOI aims to enhance profitability, expand market presence, and lead in value-based oncology care.

The Oncology Institute reports strong Q2 growth amid margin challenges

TOI's Q2 2024 earnings call reflected strong revenue growth but challenges with margins and profitability. The company is focused on addressing margin pressures and enhancing shareholder value through strategic initiatives.

The Oncology Institute reports robust Q3 growth and strategic focus

TOI's Q3 2024 performance reflects strong revenue growth, cost management, and strategic initiatives to drive operational efficiency and compliance.
The company's strengths lie in proactive cost optimization, expanded service offerings, and a clear strategic direction towards growth and performance.
Challenges include regulatory compliance, profitability sustainability, and ongoing efforts to balance financial flexibility with quality care delivery.
Opportunities abound in stable revenue streams, strategic partnerships, and enhanced profitability through optimized cost structures and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

CERRITOS, Calif. and AUSTIN, Texas , May 4, 2023 /PRNewswire/ -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced today that they have entered into a formal agreement to make IDEOlogy Health its exclusive provider of multi-channel medical education for its healthcare providers.

The Oncology Institute Announces a Strategic Partnership with IDEOlogy Health to Provide Customized Medical Education

CERRITOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2023 financial results after the market close on Wednesday, May 10, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces First Quarter 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- The Company recorded adjustments to its “goodwill impairment charges” and “income tax benefit” line items on the “Consolidated Statements of Operations” for the fourth quarter and year ended December 31, 2022 resulting from the simultaneous equation from tax deductible goodwill, resulting in a $1.5 million increase to the Company's net loss for the fourth quarter ended December 31, 2022 and a $1.5 million decrease to the Company's net income for the year ended December 31, 2022. The Company also adjusted the balances of “other receivables,” “goodwill,” “income taxes payable” "accrued expenses and other current liabilities", “deferred income taxes liability”, and "accumulated deficit" on the “Consolidated Balance Sheets” as of December 31, 2022 as well as the related reconciling items in the Company's “Consolidated Statements of Cash Flows” for the fourth quarter and year ended December 31, 2022.

CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023

The Oncology Institute, Inc. (NASDAQ:TOI ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies Sandy Draper - Guggenheim Gary Taylor - Cowen & Company Operator Good afternoon, and welcome to The Oncology Institute's Fourth Quarter and Year-End 2022 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q4 2022 Earnings Call Transcript

CERRITOS, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2022.

The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023

Brookfield Asset Management

Brookfield Corp

Part 1 features 5 stocks I am currently buying, very comfortable with, and plan to hold indefinitely, like a home. They are Brookfield Corp, Brookfield Asset Management, Topicus, Dream Unlimited Corp, and SSC Security Services Corp.

10 Top Picks For 2023 And Beyond - Part 1: Home Stocks

CERRITOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter & full year 2022 financial results after the market close on Thursday, March 9, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces Fourth Quarter & Full Year 2022 Earnings Release Date and Conference Call

CERRITOS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, has acquired the Chino, CA practice of Dr. Labib Hashimi. The acquisition enhances TOI's geographic coverage in California, with the Chino practice marking TOI's 42nd clinic in the Golden State.

The Oncology Institute Expands Into Chino, CA

TOI continues expansion in South Florida TOI continues expansion in South Florida

The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto Ochoa

The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies Sandy Draper - Guggenheim Operator Good afternoon, and welcome to The Oncology Institute's Third Quarter 2022 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q3 2022 Earnings Call Transcript

CERRITOS, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its third quarter ended September 30, 2022.

The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance

CERRITOS, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, and its Chief Financial Officer, Mihir Shah, will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes on Thursday, November 10.

The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare Conference

Topicus.com Inc. has a strong history of creating shareholder value, and is owned by one of the greatest serial acquirers in financial market history. The inflation driven market turmoil of 2022 has hit software companies the hardest, providing companies with experienced management teams and cash opportunities to salvage through the wreckages that remain.

Topicus.com: Just Buy Constellation Software Instead

Publicly traded company leaders will share perspectives on the future of value-based oncology care Publicly traded company leaders will share perspectives on the future of value-based oncology care

The Oncology Institute Executives to Speak at Key Industry Conferences in Q4

Value-based Oncology Leader Improving Access to Cutting-Edge Therapies Value-based Oncology Leader Improving Access to Cutting-Edge Therapies

The Oncology Institute Enrolls Nation's First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

Expands board to 9 members with deep healthcare management and investment experience Expands board to 9 members with deep healthcare management and investment experience

The Oncology Institute Appoints Two New Board Members

CERRITOS, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, will participate on the “Next Frontier - Value Based Care for Sub-Capitation/Specialties” panel at the Nephron 2nd Annual Physician Enablement Symposium on Thursday, September 22 at 9:00am EST.

The Oncology Institute to Participate at the Nephron 2nd Annual Physician Enablement Symposium

Publicly traded leader in value-based oncology care raises standards in patient safety Publicly traded leader in value-based oncology care raises standards in patient safety

The Oncology Institute Becomes Certified as a Patient Safety Organization

CERRITOS, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have partnered to provide enhanced psychological support services for TOI patients.

The Oncology Institute Partners with Blue Note Therapeutics to Provide a Digital Therapeutic for Treating Cancer-related Anxiety and Depression Symptoms

CERRITOS, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, and its Chief Financial Officer, Mihir Shah, will participate in the Baird Newly Public Company Virtual Access Day on Wednesday, August 17 at 2:20pm EST.

The Oncology Institute to Participate at the Baird Newly Public Company Virtual Access Day

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji Phillips - Jefferies Christian Borgmeyer - Cowen Operator Good afternoon, and welcome to The Oncology Institute's Second Quarter 2022 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepare marks and Q&A.

The Oncology Institute, Inc. (TOI) CEO Brad Hively on Q2 2022 Results - Earnings Call Transcript

CERRITOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its second quarter ended June 30, 2022.

The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance

Investment to accelerate Company's expansion into new markets, bringing high-quality, value-based care to more patients Investment to accelerate Company's expansion into new markets, bringing high-quality, value-based care to more patients

The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets

Orange County-based practice of Dr. Ranjan Sapra to combine with TOI. Orange County-based practice of Dr. Ranjan Sapra to combine with TOI.

The Oncology Institute Continues Southern California Expansion

CERRITOS, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000Ò and Russell 3000Ò Indexes after the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, according to a preliminary list of additions posted June 3.

News for The Oncology Institute Stock (TOI)